Celtrix Receives Additional U.S. Patents.SANTA CLARA, Calif.--(BUSINESS WIRE)--Dec. 7, 1995--Celtrix Pharmaceuticals, Inc. (Nasdaq: CTRX) announced today that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has granted the company three additional patents important to the development and commercialization of its IGF-BP3 complex, SomatoKine(R). A method patent on SomatoKine was issued earlier this year and two patents were issued recently related to Celtrix's production methods, which the company believes have broad application beyond SomatoKine. -0- -- U.S. Patent No. 5,407,913 on methods for systemic treatment of tissue injury -- This patent claims methods for enhancing healing in burn, trauma and surgical patients by enteral or parenteral administration of a complex of insulin-like growth factor insulin-like growth factor one of the twenty or so substances, additional to the classic bone-regulating hormones, which exert an effect on bone cell metabolism. See also somatomedin C. (IGF-I IGF-I see somatomedin C. IGF-I Insulin-like growth factor I, somatomedin-C A polypeptide hormone structurally similar to proinsulin, synthesized in the liver and fibroblasts, giving fibroblasts a paracrine function; serum levels correlate with ) and its binding protein (BP3). -- U.S. Patent No. 5,470,727 on chromosomal expression of heterologous genes in bacterial cells -- This patent relates to a novel technology for the expression of recombinant genes. It covers a method for creating a transfer DNA (carrying a gene encoding a protein of interest) and integrating the transfer DNA into the chromosome of a bacterial cell to produce recombinant protein. The claim is generic to any non-bacterial protein of interest. -- U.S. Patent No. 5,459,051 on methods and vectors for over- expression of ubiquitin u·biq·ui·tin n. A polypeptide found in all eukaryotic cells, including plant cells, that participates in a variety of cellular functions including protein degradation. fusion proteins in host cells -- The claims, which include composition of matter and methods, relate to technology used to increase the recombinant expression of fusion proteins containing ubiquitin. The claims are generic to any protein of interest fused to ubiquitin. "These three additional patents strengthen our proprietary position on SomatoKine, Celtrix's lead product candidate," commented Andreas Sommer, Ph.D., company president and chief executive officer. "SomatoKine is currently under development and expected to enter human clinical testing in spring 1996." "Celtrix's strategy with SomatoKine is to initially focus on patients who could potentially benefit from short-term hormone replacement therapy Hormone Replacement Therapy Definition Hormone replacement therapy (HRT) is the use of synthetic or natural female hormones to make up for the decline or lack of natural hormones produced in a woman's body. , such as those undergoing gastrointestinal surgery or those suffering from kidney failure or severe burns," Dr. Sommer said. "Through current and future collaborative agreements, we plan to build toward capturing increasingly larger market opportunities, which could include the treatment of wasting diseases associated with cancer, AIDS, chronic obstructive pulmonary disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. , short bowel syndrome Short bowel syndrome A condition in which the bowel is not as long as normal, either because of surgery or because of a congenital defect. Because the bowel has less surface area to absorb nutrients, it can result in malabsorption syndrome. , chronic renal failure chronic renal failure Chronic kidney failure Nephrology A slow decline in renal function, which may be 2º to chronic HTN, DM, CHF, SLE, or sickle cell anemia and, if extreme, leads to ESRD, mandating kidney dialysis; an abrupt decline in renal function may be , osteoporosis and neurodegenerative diseases." Celtrix is a biopharmaceutical company focused on developing novel therapeutics for the treatment of seriously debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction , degenerative conditions primarily associated with severe trauma, chronic diseases or aging. Company programs target the treatment of acute nutritional deficiencies and muscle wasting. Corporate partner programs extend these opportunities to include osteoporosis, tissue repair and multiple sclerosis. CONTACT: Celtrix Pharmaceuticals, Inc., Santa Clara Mary Anne Ribi, 408/988-2500 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion